Cord Blood America to provide BioE's PrepaCyte CB Processing System for its Las Vegas operations

Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has contracted with BioE, St. Paul, Minnesota, to provide the newest "state of the art" cord blood processing systems for its Las Vegas operations.  This includes BioE's PrepaCyte® CB Processing System, which efficiently separates stem cells from cord blood for cryopreservation and eventual transplantation in humans.

The PrepaCyte CB Processing System:

• Provides optimum stem cell recoveries on each cord blood unit processed.
• Ensures the sterility and integrity of the cord blood unit.
• Removes 99.5 percent of the unnecessary red cells, which offers a more pure concentration of stem cells compared to any other product or method in the industry.

"BioE's cord blood processing system helps Cord Blood America meet its objective of providing the highest quality of cord blood storage for our clients," said Matthew Schissler, co-founder and CEO.  "We are committed to offering our clients an unsurpassed level of processing and storage quality.  The BioE system does just that; one that our shareholders can revel in, and comforts our customers."